Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Cystinosis

¹Department of Pediatrics, University of Michigan, Ann Arbor 48109-2029, USA.

Journal of Inherited Metabolic Disease

|January 1, 1995

Summary

This summary is machine-generated.

Nephropathic cystinosis, a metabolic disorder causing cystine buildup, leads to severe kidney and eye issues. Early cysteamine treatment can prevent kidney failure but doesn't cure eye damage.

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Expression of CTNS alleles: subcellular localization and aminoglycoside correction in vitro.

Molecular genetics and metabolism·2002

Same author

Treatment of urea cycle disorders.

The Journal of pediatrics·1999

Same author

Characterization of cysteamine as a potential contraceptive anti-HIV agent.

Journal of andrology·1998

Same author

Safety and feasibility of liver-directed ex vivo gene therapy for homozygous familial hypercholesterolemia.

Annals of surgery·1996

Same author

Detection and characterization of a transport system mediating cysteamine entry into human fibroblast lysosomes. Specificity for aminoethylthiol and aminoethylsulfide derivatives.

The Journal of biological chemistry·1995

Same author

Recent advances in the treatment of cystinosis.

Journal of inherited metabolic disease·1995

Same journal

Biallelic Loss-Of-Function Variant in ATP5ME Is Associated With Severe and Early Onset Oxidative Phosphorylation Deficiency.

Journal of inherited metabolic disease·2026

Same journal

Beyond Upper Airway Involvement: Evidence of Intrinsic Lung Disease in a Mouse Model of Mucopolysaccharidosis I.

Journal of inherited metabolic disease·2026

Same journal

Immune Dysregulation in Branched Chain Organic Acidemias.

Journal of inherited metabolic disease·2026

Same journal

Long Term Follow-Up After Transplantation in Propionic Acidemia: A Retrospective French Pediatric and Adult Cohort Study.

Journal of inherited metabolic disease·2026

Same journal

Tri-Parametric Assessment of α-Galactosidase A Activity, lysoGb3 and X-Inactivation Aids Genotype-Phenotype Categorization of Fabry Disease Female Patients.

Journal of inherited metabolic disease·2026

Same journal

Mapping the Severity of Phenylalanine Hydroxylase Deficiency.

Journal of inherited metabolic disease·2026

See all related articles

Area of Science:

Biochemistry
Genetics
Pediatric Nephrology

Background:

Nephropathic cystinosis is an inherited metabolic disorder.
Characterized by lysosomal cystine accumulation.
Leads to Fanconi syndrome, renal failure, and ocular disease.

Purpose of the Study:

Review current understanding of nephropathic cystinosis.
Discuss gene identification strategies.
Evaluate cysteamine therapy and pathophysiological effects.

Main Methods:

Review of existing literature on cystinosis.
Analysis of gene identification approaches.
Assessment of cysteamine efficacy and limitations.

Main Results:

Cysteamine therapy prevents end-stage renal disease.
Systemic cysteamine does not resolve corneal cystine deposits.
Molecular defects remain largely unidentified for all forms.

Conclusions:

Nephropathic cystinosis requires ongoing research for gene discovery.
Cysteamine is crucial for managing renal complications.
Ocular manifestations necessitate further therapeutic development.